Luspatercept
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Luspatercept: From Unspecified Indication to Monosomy X
One-Sentence Summary
Luspatercept’s (DrugBank DB12281) original indication and mechanism of action are not documented in the current evidence pack. The TxGNN model predicts potential relevance to Monosomy X, but this direction is currently supported by 0 clinical trials and 0 publications, and the mechanistic rationale for this specific pairing has not yet been established in the underlying analysis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack |
| Predicted New Indication | Monosomy X |
| TxGNN Prediction Score | 96.00% |
| Evidence Level | L5 |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Luspatercept is not currently available in this evidence pack, and no original indication is on file to compare against. Without either of these, the mechanistic relationship between Luspatercept and Monosomy X cannot be assessed — the rationale field for this specific prediction has not yet been populated by the analysis pipeline.
For context, other TxGNN-predicted indications for this drug in the same batch (hepatic infarction, hepatic veno-occlusive disease, peliosis hepatis, syndrome with combined immunodeficiency) were explicitly reviewed and received a Hold recommendation, with the reviewers noting weak or absent mechanistic plausibility relative to Luspatercept’s known biology (an activin/GDF-pathway ligand trap acting on late-stage erythroid maturation). This suggests the overall prediction batch for this drug should be treated cautiously until mechanism-level review is completed for the top-ranked candidate as well.
No clinical trials or literature currently exist for the Luspatercept–Monosomy X pairing, so the prediction rests solely on the TxGNN model score at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Luspatercept currently holds no marketing authorisations in Denmark (market status: Not Marketed). No dosage forms, product names, or licensed indications are on file.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Monosomy X) has no supporting clinical trials or literature (Evidence Level L5) and its mechanistic rationale has not yet been documented. Combined with the absence of MOA data, absence of Danish market presence, and a blocking data gap on regulatory safety warnings/contraindications, there is currently insufficient basis to advance this candidate.
To proceed, the following is needed:
- SmPC/regulatory warnings and contraindications (blocking gap — required before any safety pre-assessment)
- Mechanism of action (MOA) data for Luspatercept
- A completed mechanistic rationale for the Monosomy X prediction specifically (currently marked pending)
- Any emerging clinical trial or literature evidence for this drug-disease pairing
- Given that related predictions in this batch (hepatic infarction, VOD, peliosis hepatis, combined immunodeficiency) were already assessed as mechanistically implausible, a dedicated plausibility review of the Monosomy X prediction before further investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.